Health product recall

Sanofi-Aventis Avalide Product Recall(2021-06-14)

Starting date:
June 14, 2021
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type I
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-75849



Last updated:
2021-06-16

Summary

  • Product:
    A. Avalide 300-12.5 mg

    B. Avalide 150-12.5 mg

Reason

Presence of impurity 5-(4-(azidomethyl)-[1,1-biphenyl]-2-yl)-1H-tetrazole above the acceptable concentration

limit in affected lot.

Depth of distribution

Retailers, Other (healthcare practioners)

Affected products

A. Avalide 300-12.5 mg

DIN, NPN, DIN-HIM

DIN 02241819

Dosage form

Tablet

Strength

Irbesartan 300 mg

Hydrochlorothiazide 12.5 mg

Lot or serial number

FT01644

Companies

Recalling Firm

Sanofi-Aventis Canada Inc.

2905 Place Louis.R-Renaud

Laval

H7V 0A3

Quebec

CANADA

Marketing Authorization Holder

Sanofi-Aventis Canada Inc.

2905 Place Louis.R-Renaud

Laval

H7V 0A3

Quebec

CANADA


B. Avalide 150-12.5 mg

DIN, NPN, DIN-HIM

DIN 02241818

Dosage form

Tablet

Strength

Irbesartan 150 mg

Hydrochlorothiazide 12.5 mg

Lot or serial number

ET02879, FT01327

Companies

Recalling Firm

Sanofi-Aventis Canada Inc.

2905 Place Louis.R-Renaud

Laval

H7V 0A3

Quebec

CANADA

Marketing Authorization Holder

Sanofi-Aventis Canada Inc.

2905 Place Louis.R-Renaud

Laval

H7V 0A3

Quebec

CANADA


Report a problem or mistake on this page
What was wrong?

If you want to receive a follow-up reply, please include your name and e-mail address.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Date modified: